T. Its been awhile but the FDA refused to approve the Anchor indication ( TG's below 500 mg/dl ) because they felt patients would be using Vascepa this way to reduce CV event risk ...rather than risk of Pancreatitis ( TG's over 500 mg/dl ) .
So they forced AMRN to complete the R-IT trial to prove that Vascepa would reduce CV events
tatsumaki, if you go back to when vascepa was originally called Mirazion when it was owned by Elan. Vascepa AMR 101 was known as the Laxdale agreement and if you look at the bios of some of the past management team and current management team/ BOD many were part of the original Wyeth/Elan crew. Amarin has a very interesting background. The management knew there was a potential blockbuster with EPA fast forward there are now 15 subsets of use and they are still discovering new applications. It's truly an amazing drug. We need BP to take over the future of Vazkepa. Many familiar names are associated with the Elan group up to Sofinnova/Ekman.
News 
Market Data 
Discover 
AI
